Akers Biosciences Further Extends Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test THOROFARE, N.J., July 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies,...

Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test THOROFARE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies,...

Akers Biosciences' Flagship Test for Heparin-Induced Thrombocytopenia Granted Approval by Chinese Food and Drug Administration THOROFARE, N.J., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare...